Ekin Nurhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekin Nurhan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Ozen
Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey
2 shared publications - Ayca Kiykim
Department of Pediatric Allergy and Immunology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
2 shared publications - Betul Gemici Karaaslan
Cerrahpasa Faculty of Medicine, Department of Pediatric Allergy and Immunology Istanbul University‐Cerrahpasa Istanbul Turkiye
2 shared publications - Burak Doğangün
Cerrahpasa Faculty of Medicine, Department of Child and Adolescent Psychiatry Istanbul University‐Cerrahpasa Istanbul Turkiye
2 shared publications - Cigdem Aydogmus
Department of Pediatric Allergy and Immunology Basaksehir Cam and Sakura City Hospital Istanbul Turkiye
2 shared publications - Elif Karakoc-Aydiner
Pediatric Allergy and Immunology, Marmara University School of Medicine, Istanbul, Türkiye
2 shared publications
Latest Publications
- 2 November 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (11)
When cure is not enough: Parental anxiety, depression, and caregiver burden after HSCT for inborn errors of immunity
Introduction: Hematopoietic stem cell transplantation (HSCT) is curative for many children with inborn errors of immunity (IEIs). While research has largely focused on survival, immune reconstitution, and transplant‐related complications, the long‐term psychosocial impact on families of medically stable, complication‐free survivors remains poorly understood. Methods: In this cross‐sectional case–control study, 79 children with IEIs who achieved full immune reconstitution after HSCT and were free of chronic disease‐ or transplant‐related complications were compared with 69 age‐ and sex‐matched healthy controls. Parents completed the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Zarit Burden Interview (ZBI). Caregivers also completed the parent‐report Strengths and Difficulties Questionnaire (SDQ). Linear regression analysis was performed to identify factors associated with caregiver burden. Results: Mothers of transplanted children had significantly higher depression, anxiety, and caregiver burden scores than control mothers (all p ≤ .001). Fathers demonstrated higher depression scores, whereas anxiety scores did not differ significantly. Maternal depression independently predicted caregiver burden ( β = .913, 95% CI 0.512–1.314, p < .001). Children in the patient group showed higher conduct problem and hyperactivity scores, with a trend toward greater internalizing difficulties. Psychological outcomes were not associated with demographic characteristics, disease‐related factors, or time since transplantation. Discussion: Despite successful immune reconstitution and the absence of chronic complications, families continued to experience substantial psychosocial burden. Maternal depressive symptoms emerged as the strongest determinant of caregiver burden. These findings suggest that medical recovery after HSCT does not necessarily translate into psychosocial recovery and support the integration of routine family‐centered psychological assessment into long‐term follow‐up care. image
- 2 November 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (11)
When cure is not enough: Parental anxiety, depression, and caregiver burden after HSCT for inborn errors of immunity
Introduction: Hematopoietic stem cell transplantation (HSCT) is curative for many children with inborn errors of immunity (IEIs). While research has largely focused on survival, immune reconstitution, and transplant‐related complications, the long‐term psychosocial impact on families of medically stable, complication‐free survivors remains poorly understood. Methods: In this cross‐sectional case–control study, 79 children with IEIs who achieved full immune reconstitution after HSCT and were free of chronic disease‐ or transplant‐related complications were compared with 69 age‐ and sex‐matched healthy controls. Parents completed the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Zarit Burden Interview (ZBI). Caregivers also completed the parent‐report Strengths and Difficulties Questionnaire (SDQ). Linear regression analysis was performed to identify factors associated with caregiver burden. Results: Mothers of transplanted children had significantly higher depression, anxiety, and caregiver burden scores than control mothers (all p ≤ .001). Fathers demonstrated higher depression scores, whereas anxiety scores did not differ significantly. Maternal depression independently predicted caregiver burden ( β = .913, 95% CI 0.512–1.314, p < .001). Children in the patient group showed higher conduct problem and hyperactivity scores, with a trend toward greater internalizing difficulties. Psychological outcomes were not associated with demographic characteristics, disease‐related factors, or time since transplantation. Discussion: Despite successful immune reconstitution and the absence of chronic complications, families continued to experience substantial psychosocial burden. Maternal depressive symptoms emerged as the strongest determinant of caregiver burden. These findings suggest that medical recovery after HSCT does not necessarily translate into psychosocial recovery and support the integration of routine family‐centered psychological assessment into long‐term follow‐up care. image
- Open Access
- 19 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Canakinumab dosing intervals in pediatric colchicine-resistant FMF: outcomes and predictors of successful extension in a real-world cohort
Objectives: Canakinumab is widely used in colchicine-resistant familial Mediterranean fever (FMF), yet data on interval adjustment strategies and predictors of successful extension remain limited. This study evaluated clinical and inflammatory outcomes across dosing interval groups and identified factors associated with successful interval extension. Methods: This retrospective single-centre study included 60 pediatric patients with colchicine-resistant FMF treated with canakinumab. Patients were stratified into stable interval (group 1, n = 14), successful interval extension (group 2, n = 24) and unsuccessful interval extension (group 3, n = 22). Longitudinal C-reactive protein (CRP) trajectories were analysed using linear mixed-effects models. Clinical outcomes were compared across groups, and predictors of successful interval extension were assessed using multivariable logistic regression with Firth’s penalized method as a sensitivity analysis. Results: Following canakinumab initiation, CRP levels declined rapidly and stabilized after month 3, while the median annual attack rate decreased from 7 (4–12) to 1.1 (0.5–2.1) attacks per patient-year. Inflammatory trajectories did not differ across groups. Despite similar CRP dynamics, complete remission rates differed significantly (57.1%, 45.8% and 27.3% in Groups 1–3, respectively; P = 0.005), and all patients in group 3 experienced attacks. Arthritis at disease onset was independently associated with successful interval extension (OR = 7.14, 95% CI 1.26–40.41, P = 0.026), with consistent direction in Firth analysis (OR = 5.51, 95% CI 1.08–28.23, P = 0.081). Conclusion: Although canakinumab achieves sustained inflammatory suppression, biochemical improvement does not ensure comparable clinical control. Clinical phenotype, particularly arthritis at onset, may guide individualized interval adjustment.
- 19 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Open AccessCanakinumab dosing intervals in pediatric colchicine-resistant FMF: outcomes and predictors of successful extension in a real-world cohort
Objectives: Canakinumab is widely used in colchicine-resistant familial Mediterranean fever (FMF), yet data on interval adjustment strategies and predictors of successful extension remain limited. This study evaluated clinical and inflammatory outcomes across dosing interval groups and identified factors associated with successful interval extension. Methods: This retrospective single-centre study included 60 pediatric patients with colchicine-resistant FMF treated with canakinumab. Patients were stratified into stable interval (group 1, n = 14), successful interval extension (group 2, n = 24) and unsuccessful interval extension (group 3, n = 22). Longitudinal C-reactive protein (CRP) trajectories were analysed using linear mixed-effects models. Clinical outcomes were compared across groups, and predictors of successful interval extension were assessed using multivariable logistic regression with Firth’s penalized method as a sensitivity analysis. Results: Following canakinumab initiation, CRP levels declined rapidly and stabilized after month 3, while the median annual attack rate decreased from 7 (4–12) to 1.1 (0.5–2.1) attacks per patient-year. Inflammatory trajectories did not differ across groups. Despite similar CRP dynamics, complete remission rates differed significantly (57.1%, 45.8% and 27.3% in Groups 1–3, respectively; P = 0.005), and all patients in group 3 experienced attacks. Arthritis at disease onset was independently associated with successful interval extension (OR = 7.14, 95% CI 1.26–40.41, P = 0.026), with consistent direction in Firth analysis (OR = 5.51, 95% CI 1.08–28.23, P = 0.081). Conclusion: Although canakinumab achieves sustained inflammatory suppression, biochemical improvement does not ensure comparable clinical control. Clinical phenotype, particularly arthritis at onset, may guide individualized interval adjustment.
- Open Access
- 13 June 2026
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (5) , 2923-2930
Beyond immune recovery: Quality of life and psychosocial challenges in children with inborn errors of immunity after transplantation
Introduction: Hematopoietic stem cell transplantation (HSCT) provides definitive treatment for many inborn errors of immunity (IEI). Although most children achieve full immune reconstitution, long-term psychosocial and quality-of-life outcomes in medically stable survivors remain insufficiently understood. Methods: Children aged 8–18 years with IEI who achieved complete immune recovery and had no chronic complications were included. Quality of life and psychological status were evaluated using the Pediatric Quality of Life Inventory (PedsQL-C) and the Revised Children’s Anxiety and Depression Scale (RCADS). Healthy children matched for age, sex, and sociodemographic background served as controls. Results: Thirty-six patients and 41 controls participated. Children post-HSCT had significantly lower physical, psychosocial, and total quality-of-life scores (p = 0.022, 0.015, 0.006) and higher depression scores (p = 0.027). One-quarter of school-aged patients were not attending school, and one-third of families restricted exposure to crowded environments. Conclusion: Despite immune recovery, children remain vulnerable to psychosocial challenges. These findings support incorporation of routine psychological assessment and family counseling into long-term post-HSCT follow‑up.
- 13 June 2026
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (5) , 2923-2930
Open AccessBeyond immune recovery: Quality of life and psychosocial challenges in children with inborn errors of immunity after transplantation
Introduction: Hematopoietic stem cell transplantation (HSCT) provides definitive treatment for many inborn errors of immunity (IEI). Although most children achieve full immune reconstitution, long-term psychosocial and quality-of-life outcomes in medically stable survivors remain insufficiently understood. Methods: Children aged 8–18 years with IEI who achieved complete immune recovery and had no chronic complications were included. Quality of life and psychological status were evaluated using the Pediatric Quality of Life Inventory (PedsQL-C) and the Revised Children’s Anxiety and Depression Scale (RCADS). Healthy children matched for age, sex, and sociodemographic background served as controls. Results: Thirty-six patients and 41 controls participated. Children post-HSCT had significantly lower physical, psychosocial, and total quality-of-life scores (p = 0.022, 0.015, 0.006) and higher depression scores (p = 0.027). One-quarter of school-aged patients were not attending school, and one-third of families restricted exposure to crowded environments. Conclusion: Despite immune recovery, children remain vulnerable to psychosocial challenges. These findings support incorporation of routine psychological assessment and family counseling into long-term post-HSCT follow‑up.